151 related articles for article (PubMed ID: 38393441)
1. Clinical characteristics and dynamics of disability progression in a cohort of patients with multiple sclerosis in Latvians.
Kalnina J; Trapina I; Sjakste N; Paramonova N
Neurol Sci; 2024 Jul; 45(7):3347-3358. PubMed ID: 38393441
[TBL] [Abstract][Full Text] [Related]
2. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
[No Abstract] [Full Text] [Related]
3. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
[TBL] [Abstract][Full Text] [Related]
4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
5. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
7. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
8. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
Usta NC; Boz C; Terzi M
Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
[TBL] [Abstract][Full Text] [Related]
9. The natural history of early versus late disability accumulation in primary progressive MS.
Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
11. Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study.
Cortesi PA; Fornari C; Capra R; Cozzolino P; Patti F; Mantovani LG
Value Health; 2022 Sep; 25(9):1489-1498. PubMed ID: 35484029
[TBL] [Abstract][Full Text] [Related]
12. Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
Ouallet JC
Rev Neurol (Paris); 2020 Jun; 176(6):500-504. PubMed ID: 32278541
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of multiple sclerosis with early onset.
Ghezzi A; Pozzilli C; Liguori M; Marrosu MG; Milani N; Milanese C; Simone I; Zaffaroni M
Mult Scler; 2002 Apr; 8(2):115-8. PubMed ID: 11990867
[TBL] [Abstract][Full Text] [Related]
14. Modelling the natural history of primary progressive multiple sclerosis.
Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
[TBL] [Abstract][Full Text] [Related]
15. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
[TBL] [Abstract][Full Text] [Related]
16. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
17. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
[TBL] [Abstract][Full Text] [Related]
18. Long-term disability progression of pediatric-onset multiple sclerosis.
McKay KA; Hillert J; Manouchehrinia A
Neurology; 2019 Jun; 92(24):e2764-e2773. PubMed ID: 31092624
[TBL] [Abstract][Full Text] [Related]
19. Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.
Zhang T; Kingwell E; De Jong HJ; Zhu F; Zhao Y; Carruthers R; Petkau J; Gustafson P; Oger J; Tremlett H
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1150-1159. PubMed ID: 27211481
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Multiple Sclerosis in Rio de Janeiro: Secondary Progression and Disability.
Cerqueira Pinto SC; Ferreira Vasconcelos CC; Aurenção JCK; Alvarenga MP; das Graças Gomes Camargo SM; Santos Thuler LC; Alvarenga RP
Pediatr Neurol; 2019 May; 94():48-54. PubMed ID: 30850228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
